New insider Richton Kathleen P. claimed ownership of 6,900 shares (SEC Form 3)
$ENGN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 07/16/2026 | 3. Issuer Name and Ticker or Trading Symbol
enGene Therapeutics Inc. [ ENGN ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Shares | 6,900(1) | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (Right to Buy) | (2) | 01/29/2035 | Common Shares | 45,000 | $7.39 | D | |
| Stock Option (Right to Buy) | (3) | 01/30/2036 | Common Shares | 13,900 | $9.53 | D | |
| Stock Option (Right to Buy) | (4) | 06/16/2036 | Common Shares | 105,000 | $1.75 | D | |
| Explanation of Responses: |
| 1. Consists of 6,900 unvested restricted stock units (RSUs) granted to the Reporting Person on January 30, 2026 pursuant to the Issuer's Amended and Restated 2023 Incentive Equity Plan (the "Plan"), which are scheduled to vest annually in substantially equal amounts for four years, commencing January 15, 2027, subject to the Reporting Person's continued service. Each RSU represents a contingent right to receive one common share of the Issuer. |
| 2. Non-qualified stock option grant awarded as an inducement award outside of the Plan in accordance with NASDAQ Listing Rule 5635(c)(4). This option vested at 25% on January 27, 2026, with the remaining portion to vest monthly in substantially equal amounts for the following 36 months, subject to the Reporting Person's continued service. |
| 3. This option vests monthly in substantially equal amounts for 48 months, commencing January 30, 2026, subject to the Reporting Person's continued service. |
| 4. This option vests monthly in substantially equal amounts for 48 months, commencing June 16, 2026, subject to the Reporting Person's continued service. |
| Remarks: |
| Exhibit 24 - Power of Attorney |
| /s/ Kathleen P. Richton | 07/22/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||